Table 5 Mean per-patient costs (US$) by type of treatment initiated following first-line therapy (n = 82 with complete RU data)
From: The economic burden of advanced gastric cancer in Taiwan
Type of costs | Costs during follow-up | Annual costsa | ||
|---|---|---|---|---|
BSC (n = 20) | 2nd-line TX (n = 62) | BSC (n = 20) | 2nd-line TX (n = 62) | |
Mean follow-up days (SD) | 401 (251) [Median: 305] | 458 (334) [Median: 338] | – | – |
Direct medical costs, mean(SD) | 24,911 (11,661) | 25,938 (17,279) | 27,583 (15,051) | 26,059 (15,512) |
Inpatient costs | 8386 (13,127) | 7741 (8913) | 8119 (11,093) | 7393 (7835) |
Outpatient costs | 3074 (2715) | 3116 (2078) | 3340 (2508) | 3049 (1752) |
Chemotherapy related costs | 13,451 (6223) | 15,081 (13,174) | 16,124 (10,140) | 15,617 (11,291) |
- Drug costs | 9240 (5184) | 10,570 (11,974) | 11,205 (7665) | 10,817 (9975) |
- Drug administration costs | 3355 (3017) | 3524 (2520) | 4045 (4224) | 3907 (2874) |
- Costs of routine examinations | 856 (537) | 987 (669) | 874 (311) | 892 (299) |
Direct non-medical costs, mean(SD) | 4232 (2227) | 4476 (2655) | 4815 (2813) | 4622 (2362) |
Transportation costs | 629 (401) | 678 (461) | 718 (432) | 698 (354) |
Caregiver costs | 3602 (1925) | 3798 (2250) | 4098 (2435) | 3925 (2057) |
Morbidity costs | 5325 (2824) | 5531 (3276) | 6042 (3538) | 5666 (2905) |